Correction: Earns-ImmunoGen

AP News
Posted: Apr 29, 2011 6:25 PM
Correction: Earns-ImmunoGen

In a story April 28 about ImmunoGen's third-quarter earnings, The Associated Press reported erroneously that ImmunoGen licensed trastuzumab emtansine to Roche. ImmunoGen licensed technology used in the drug to Roche.

The story also didn't make clear that trastuzumab emtansine combines trastuzumab, which is marketed as Herceptin, with ImmunoGen's DM1 cancer-cell killing technology.

In addition to the mid-stage clinical trial, Roche/Genentech is running a late-stage clinical study of trastuzumab emtansine as a primary treatment for breast cancer.

Trastuzumab emtansine is being studied as a treatment for HER2-positive breast cancer, a more aggressive type of the disease which is less responsive to hormone treatment.